

Meta-analysis of the association between obstructive sleep apnoea and postoperative outcome

R. Kaw^{1,2*}, F. Chung³, V. Pasupuleti⁴, J. Mehta³, P. C. Gay^{6,7} and A. V. Hernandez⁵

¹ Department of Hospital Medicine and ² Department of Outcomes Research (Anesthesiology), Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA

³ Department of Anesthesia, University Health Network, University of Toronto, Ontario, Canada

⁴ Department of Molecular Cardiology and ⁵ Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

⁶ Department of Neurology and ⁷ Department of Pulmonary and Critical Care Medicine and Sleep, Mayo Clinic, Rochester, MN, USA

* Corresponding author. E-mail: kawr@ccf.org

Editor's key points

- Patients with obstructive sleep apnoea (OSA) may have a higher incidence of postoperative complications.
- Meta-analysis of OSA and outcome limited by considerable variation between studies in definitions used.
- OSA was associated with increased incidence of desaturation, respiratory failure, cardiac events, and intensive care unit admission.

Background. Obstructive sleep apnoea (OSA) is often undiagnosed before elective surgery and may predispose patients to perioperative complications.

- Methods. A literature search of PubMed-Medline, Web of Science, Scopus, EMBASE, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials up to November 2010 was conducted. Our search was restricted to cohort or case-control studies in adults diagnosed with OSA by screening questionnaire, oximetry, or polysomnography. Studies without controls, involving upper airway surgery, and with OSA diagnosed by ICD-9 codes alone were excluded. The primary postoperative outcomes were desaturation, acute respiratory failure (ARF), reintubation, myocardial infarction/ischaemia, arrhythmias, cardiac arrest, intensive care unit (ICU) transfer, and length of stay.
- **Results.** Thirteen studies were included in the final analysis (n=3942). OSA was associated with significantly higher odds of any postoperative cardiac events [45/1195 (3.76%) vs 24/1420 (1.69%); odds ratio (OR) 2.07; 95% confidence interval (CI) 1.23–3.50, P=0.007] and ARF [33/ 1680 (1.96%) vs 24/3421 (0.70%); OR 2.43, 95% CI 1.34–4.39, P=0.003]. Effects were not heterogeneous for these outcomes ($I^2=0-15\%$, P>0.3). OSA was also significantly associated with higher odds of desaturation [189/1764 (10.71%) vs 105/1881 (5.58%); OR 2.27, 95% CI 1.20–4.26, P=0.01] and ICU transfer [105/2062 (5.09%) vs 58/3681 (1.57%), respectively; OR 2.81, 95% CI 1.46–5.43, P=0.002]. Both outcomes showed a significant degree of heterogeneity of the effect among studies ($I^2=57-68\%$, P<0.02). Subgroup analyses had similar conclusions as main analyses.

Conclusions. The incidence of postoperative desaturation, respiratory failure, postoperative cardiac events, and ICU transfers was higher in patients with OSA.

Keywords: complications; sleep apnoea; surgery

Accepted for publication: 10 July 2012

In North America, moderately severe obstructive sleep apnoea (OSA) with an apnoea-hypopnoea index (AHI) >15 is present in 11.4% of men and 4.7% of women, respectively.¹⁻³ OSA is associated with several co-morbidities such as cardiovascular disease, heart failure, arrhythmias, hypertension, cerebrovascular disease, and metabolic syndrome.⁴⁻⁷ In patients going for elective surgery, the prevalence of OSA is substantially higher compared with that of the general population.^{8 9} Some recent studies report a incidence of >30% in neurosurgical patients and up to 91% in patients undergoing bariatric surgery.¹⁰⁻¹² When screened using the Berlin questionnaire,⁸ about 24% patients were noted to be at risk of having OSA, as opposed to 27.5%¹³ using STOP (Snoring, Tiredness, Observed apnoeas and high blood pressure) questionnaire. OSA can pose a significant challenge to anaesthetists in the perioperative period due to possible difficult intubation, increased sensitivity to opioids and postoperative upper airway obstruction,¹⁴ the physiological interaction of cross-sectional area, lung volume, and driving pressure changes, body position effects, and fat distribution.¹⁵ ¹⁶

Review of the literature shows that the majority of studies have shown a higher overall postoperative complication rate in patients with OSA compared with the general population. Significant variation, however, has been noted in the reporting of these complications between different studies. For

Kaw et al.

example, most studies associate OSA with respiratory complications, but similar association with major complications such as postoperative respiratory failure is not clear. Unanticipated intensive care unit (ICU) transfers after surgery were not reported by some studies, but in others, some ICU transfers were electively scheduled before surgery, and some studies were designed as quality improvement (QI) projects with the explicit goal of minimizing transfers to ICU. There are a number of reasons for this variation, including: whether OSA was diagnosed clinically, by screening or by a gold standard test, whether the comparison was against a group of 'true controls' [OSA excluded by formal polysomnography (PSG)], sample size, whether the study was designed primarily as a QI project to mitigate adverse outcomes, and whether the patients were on treatment with positive airway pressure therapy before surgery and perioperatively. The objective of this meta-analysis is to examine the evidence linking the presence of OSA in patients undergoing elective surgery with perioperative complications.

Methods

Search strategy and study selection

We screened abstracts of published observational studies evaluating the association OSA and postoperative complications in patients undergoing non-cardiac surgery. A literature search was conducted by four authors (R.K., V.P., J.M., and A.V.H.) in PubMed-Medline (1960-October 31, 2010), the Web of Science (1980-October 31, 2010), Scopus (1960-October 31, 2010), the Cochrane Database of Systematic Reviews (2005-October 2010), and the Cochrane Central Register of Controlled Trials (4th quarter 2010). The search used the MESH keywords 'sleep apnea, obstructive' and 'postoperative period' and also the text keywords 'postoperative' and 'complications' or 'outcome', 'perioperative care', 'intraoperative care', 'postoperative care', 'intraoperative monitoring', 'postoperative monitoring', 'perioperative complications', 'intraoperative complications', 'postoperative complications', 'outcome', 'risk', 'morbidity', 'mortality' and 'death' and also 'obstructive sleep apnea', 'obstructive sleep apnea syndrome', 'obstructive sleep apnoea', 'obstructive sleep apnoea syndrome', 'sleep disordered breathing', 'obesity hypoventilation syndrome', 'apnea or apnoea', 'hypopnea or hypopnoea'. The full search strategy used in PubMed is shown in the Appendix.

Our search was restricted to cohort or case-control studies in adult (>18 yr old) patients, with information available on at least one postoperative complication/outcome in patients with and without OSA, published in any language. Patients may have been diagnosed before operation with OSA either by screening questionnaire, oximetry, or PSG. We excluded studies without information on control patients (i.e. those without OSA), studies where patients underwent upper airway surgery, or if the diagnosis of OSA was on the basis of ICD-9 codes alone. Abstracts were reviewed independently by two investigators (R.K. and V.P.), and full-text articles were retrieved for abstracts that fulfilled inclusion/ exclusion criteria. A manual review of references from primary or review articles was also performed.

Data extraction

Two investigators (R.K. and V.P.) extracted data, and the results were compiled. Disagreement was resolved by consensus. The following information was collected from each study: year of publication, sample size, size of OSA and control groups, type of surgery, ASA class, age, gender, BMI, history of hypertension, diabetes, coronary artery disease (CAD), heart failure (HF), cerebrovascular accident (CVA), chronic obstructive pulmonary disease, asthma, and the primary outcomes.

Primary outcomes

Our primary postoperative outcomes were any cardiac or respiratory complications. Postoperative respiratory complications were characterized as postoperative desaturation, acute respiratory failure (ARF), and tracheal reintubation. Most studies defined postoperative desaturation as oxygen desaturation \geq 4% below baseline or last recorded value for $>\!10~s^{17}$ 18 with $S\,p_{O_7}$ $<\!90\%.^{13}$ 19 20 Only three studies provided definitions for ARF; two of these on the basis of need for mechanical ventilation^{21 22} and another defined ARF as oxygen saturation <90% or hypercapnia requiring continuous positive airway pressure (CPAP), bilevel positive airway pressure, or reintubation.²³ No standard definition of cardiac complications was used by any study, but these included myocardial infarction, ischaemia, or both, new arrhythmias, tachycardia/bradycardia, hypotension, and cardiac arrest. Other major primary outcomes were ICU transfer and length of stay (LOS).

Study quality assessment

Two investigators (R.K. and V.P.) evaluated the quality of studies. The quality of studies was graded as (i) prospective cohort study, (ii) retrospective cohort study, (iii) case-control study, and (iv) cross-sectional study. We systematically assessed key points of study quality proposed by the MOOSE collaboration²⁴ including: (i) clear identification of study population, (ii) clear definition of outcome and outcome assessment, (iii) independent assessment of outcome parameters, (iv) no selective loss during follow-up, and (v) important confounders, prognostic factors, or both identified. Each point was rated as Yes/No. If a study did not clearly mention one of these key points, it was considered as No.

Statistical analysis

This study followed the reporting guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.²⁵ The Mantel-Haenzel method was used to combine categorical events, and the inverse variance method to combine continuous events. Fixed effects models were used for all analyses, as they are better when outcomes are scarce. For outcomes with substantial heterogeneity, random models were also used and shown as primary models. The measure of association for categorical events was the odds ratio (OR) for categorical outcomes and the mean difference (MD) for the continuous outcomes. Statistical heterogeneity was evaluated with the Cochran χ^2 and the I² statistics.²⁶ Publication bias was explored with the funnel plot for the outcome with the highest number of studies. When the median and IQR were provided, the mean was estimated by the formula x=(a+2m+b)/4 using the values of the median (m), P25 and P75 (a and b, respectively). We used Review Manager (RevMan, version 5.0 for Windows, Oxford, UK; The Cochrane Collaboration, 2008). To explore sources of heterogeneity between the studies, we prespecified several subgroup analyses. These included studies that defined OSA by PSG criteria, studies that excluded known OSA patients, studies that adjusted for age and BMI, studies initiated as QI projects, and studies that reported prior CPAP use.

Results

Eligible studies

A total of 6247 records were identified and reasons for excluding studies are explained in Figure 1. Only 13 studies^{17-21, 23} ²⁷⁻³³ were included in the final analysis. The total number of patients was 3942. Some studies only included ICD-9 codes for diagnosis of OSA and unique postoperative complications such as acute respiratory distress syndrome and had to be excluded from the analysis.^{22 34} Another was excluded since it only provided the median propensities and not the exact numbers for outcomes.³⁵ We contacted the authors of these studies,^{34 35} but given the specifics of each study, we were unable to obtain the data we needed for our analysis. Most of the studies had a high/moderate quality.

Study characteristics

The studies were heterogeneous (Table 1). Patients had a mean age of 57.4 (14.9) yr, and 1819 (59.6%) were male. Sixteen studies included information on at least one postoperative complication. The number of cardiac events, respiratory failure, and tracheal reintubation was low (0-13.5%), while a higher frequency was noted for desaturation and ICU transfers (0.6-40.9%). Five studies were prospective cohorts and eight retrospective cohorts (Table 2). All studies clearly identified the study populations and defined appropriately the outcomes. Three studies had selective loss of patients during follow-up, and seven studies appropriately adjusted associations for important confounders, prognostic factors, or both. Only four studies mentioned postoperative CPAP use; 14 patients out of 101;¹⁹ six patients out of 31;¹⁸ three patients out of 243;³¹ and most patients listed in Hallowell and colleagues.²⁸ There is wider mention of self-reported home CPAP use before surgery in two studies, 33/101¹⁹ and 106/282.²⁰ Owing to limited data, selfreported preoperative use of CPAP could only be analysed as a subgroup.

Meta-analysis

Patients with OSA had significantly higher odds of postoperative cardiac events in comparison with those without OSA [45/1195 (3.76%) vs 24/1420 (1.69%), respectively; OR 2.07, 95% confidence interval (CI) 1.23–3.50, P=0.007, Fig. 2A]. OSA was also associated with significantly higher odds of respiratory failure [33/1680 (1.96%) vs 24/3421 (0.70%); OR 2.43, 95% CI 1.34–4.39, P=0.003, Fig. 2B] and non-significantly higher odds of reintubation [12/1303 (0.92%) vs 18/2839 (0.63%); OR 2.05, 95% CI 0.92–4.55, P=0.08, Fig. 2c]. Effects were not heterogeneous among studies for these three outcomes ($I^2=0-15\%$, P>0.3).

The presence of OSA was significantly associated with higher odds of desaturation [189/1764 (10.71%) vs 105/ 1881 (5.58%); OR 2.27, 95% CI 1.20–4.26, P=0.01, Fig. 2_D] and ICU transfer [105/2062 (5.09%) vs 58/3681 (1.57%), respectively; OR 2.81, 95% CI 1.46–5.43, P=0.002, Fig. 2_E]. Both of these outcomes showed a significant degree of heterogeneity of the effect among studies ($I^2=57-68\%$, P<0.02). Finally, the presence of OSA was associated with a higher LOS in two studies¹⁹ ²¹ (MD 1.79 days, 95% CI 0.87–2.72, P=0.0001; $I^2=0\%$). We did not find evidence of publication bias from the evaluation of the funnel plots.

Subgroup analysis

The association between OSA and postoperative outcomes remained unchanged among the subgroup which defined OSA only on the basis of PSG criteria (Supplementary material). The association did not change in the studies that reported the prior use of CPAP among some of their patients and in studies that adjusted for age and BMI. As would be expected, studies that were initiated as QI projects found non-significant associations between OSA and all postoperative outcomes. The subgroup of studies that excluded known OSA patients also showed the same trends as the main analysis. However, due to a limited number of studies, postoperative respiratory failure and tracheal reintubation could not be evaluated.

Discussion

The principal findings are that the incidence of postoperative respiratory desaturation, respiratory failure, postoperative cardiac events, and ICU transfers was higher in patients with OSA when compared with those without OSA. Within the cohort of patients who developed postoperative ARF, the incidence of reintubation during the postoperative course was higher among the OSA patients in studies that specifically reported it but not statistically significant.

As would be anticipated, respiratory difficulties dominate the spectrum of postoperative complications in patients with OSA.

Postoperative ARF

There was a significant variation in the reporting of ARF between studies. The incidence reported did not vary with the number of patients in the study (range: n=31-661),



with both extremes reporting a low number of events. In addition, only two studies^{21 22} reported ARF using a standard definition, but only one of these could be included in the analysis. One reported respiratory failure as reintubation and/or hypercapnia needing CPAP,¹⁹ and another study²⁷ dropped all patients with adverse intraoperative events needing prolonged ventilation from the final analysis. More importantly, four out of 13 studies^{17 23 27 30} included in our analysis began as clinical practice improvement initiatives to mitigate OSA-related complications in patients considered to be at high risk. Continuous pulse oximetry was used with the aim of improving identification and preventing respiratory complications in these patients, but the type of anaesthesia, sedation, and airway management were not part of the practice improvement. Although many studies did not report the postoperative use of CPAP but the prior use of CPAP in patients with OSA ranged from 20% to 60% and this also could possibly have resulted in lowering the rate of respiratory complications. Although many studies have reported postoperative ARF in patients undergoing surgery, to our knowledge, only one study has reached statistical significance.

Despite the wide range of variability in reporting of ARF, inclusion of four studies whose main aim was to reduce the incidence of adverse postoperative events, inclusion of studies that reported the use of prior CPAP, and exclusion of two large and important studies which used ICD-9 codes, postoperative ARF was more frequent in patients with OSA compared with those without OSA. We consider this as the major finding of our analysis. However, statistical significance was reached by pooling data on this complication that this needs to be confirmed by a large prospective study. This finding was recently shown in \sim 50 000 patients

with OSA undergoing general and orthopaedic surgery.³⁴ This study, however, was not included in our analysis, given the large number of OSA patients whose diagnosis was based on inpatient diagnostic code only.

Oxygen desaturation

Oxygen desaturation was defined differently in most studies. It is unlikely that all events were captured in these retrospective studies as therapeutic interventions may have occurred on the presence of desaturation. We do not believe that episodes of transient desaturation represent events of significant hypoxia, but, in patients with OSA, these may predict further worsening of respiratory complications.

Cardiac complications

Despite the relatively low incidence of postoperative cardiac complications in the individual studies, the incidence of cardiac complications in the cohort was statistically significant. Of the nine studies¹³ ¹⁸ ²⁰ ²¹ ²³ ²⁷ ²⁸ ³¹ ³³ that reported postoperative cardiac events, three¹⁸ ²¹ ³¹ reported no adverse cardiac events, including one study of cardiac surgery patients.²¹ Two patients had cardiac arrest and five patients had MI after operation. The incidence of arrhythmias after surgery in patients varied from 1% to 6%, but most studies did not specify the type of arrhythmia. Patients with OSA have been shown to have a higher prevalence of CAD. Higher AHIs have been reported in patients with a history of MI, CAD, and cardiovascular outcomes.^{36–38}

Only one recent study, which could not be used in the analysis, provided details about treatment of intraoperative cardiovascular complications in patients with increased

Study	Study design	Diagnosis of OSA	Groups	n	Age (yr) [mean (range)]	Male [n (%)]	BMI [mean (sd)]	HTN [n (%)]	DM [n (%)]	CAD [n (%)]	COPD [n (%)]	Asthma [n (%)]	Stroke [n (%)]	Surgery type
Ahmad and colleagues ¹⁸	PC	PSG	OSA	31	43 (19.0-57.3)	8 (25.8)	50 (9)	10 (32)	8 (26)	1 (3.2)	NA	NA	NA	Abdominal
			Non-OSA	9	42 (11.5–61.1)	0 (0)	48 (6)	1 (11)	1 (11)	0 (0)	NA	NA	NA	
Chung and colleagues ³²	PC	PSG	OSA	147	59 (19.5-81.6)	83 (56.5)	30.4 (6)	72 (49)	40 (27.4)	8 (5.5)	2 (1.4)	5 (10.3)	9 (6.2)	Orthopaedic, general, ENT, ophthalmology, gynaecology, neurosurgical, urology, plastics
			Non-OSA	64	50 (18.8–77.5)	23 (35.9)	27.9 (6)	20 (31.3)	8 (12.3)	3 (4.6)	1 (1.5)	9 (13.9)	1 (1.5)	
Finkel and colleagues ²³	PC	OSA screening questionnaire	OSA	170	52.8 (22.6-84.1)	113 (54.6)	36.9 (33.5 <i>-</i> 42.0)*	116 (56)	49 (23.7)	22 (10.6)	NA	NA	3 (1.4)	Bariatric, cardiothoracic, general, gynaecology, neurosurgical
		Apnoea Risk Evaluation System (ARES)	Non-OSA	37	56 (17.8-81.6)		26.6 (23.7– 29.7)*				NA	NA		ENT, ophthalmology, orthopaedic, urology, vascular, others
Gali and colleagues ³⁰	PC	OSA questionnaire	OSA	115	59.9 (36.3–82.4)	98 (85.2)	36.0 (7.5)	NA	NA	NA	NA	NA	NA	Orthopaedic, gynaecologic,
		Sleep Apnoea Clinical Score (SACS)	Non-OSA	25	59.6 (43.3 – 76.9)	18 (72.0)	29.9 (4.5)	NA	NA	NA	NA	NA	NA	genitourinary, ENT, plastics
Gali and colleagues ²⁷	PC	OSA questionnaire	OSA	221	59.9 (28.5-82.2)	190 (86.0)	35.1 (6.0)	179 (81)	NA	NA	NA	NA	NA	Orthopaedic, thoracic, abdominal, gynaecologic, genitourinary
		Sleep Apnoea Clinical Score (SACS)	Non-OSA	472	58.2 (24.6-88.0)	203 (43.0)	30.4 (6.7)	181 (38)	NA	NA	NA	NA	NA	ENT, neurosurgery, plastics, others
Gupta and colleagues ¹⁹	RC	84% PSG	OSA	101	68.1 (48.4–85.7)	70 (69.3)	33.5 (5.7)	59 (58.4)	NA	27 (26.7)	14 (13.8)	NA	NA	Orthopaedic
		16% nocturnal oximetry	Non-OSA	101	(53.3–95.8)	70 (69.3)	30.2 (8.2)	48 (47.5)	NA	48 (47.5)	11 (10.9)	NA	NA	
Hallowell and colleagues ²⁸	RC	PSG	OSA Non-OSA	454 436	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	Bariatric
Hwang and colleagues ¹⁷	RC	Nocturnal oximetry	OSA	98	55.9 (31.5-86.3)	55 (56.1)	36.5 (8.7)	61 (62.2)	20 (20.4)	NA	3 (3.1)	16 (16.3)	3 (3.1)	Orthopaedic, thoracic, abdominal, gynaecologic, genitourinary
			Non-OSA	74	52.7 (18.7–74.4)	30 (40.5)	34.0 (9.0)	37 (45.9)	9 (12.2)	NA	4 (5.4)	13 (17.6)	3 (4.1)	ENT, cardiothoracic, vascular, neurosurgical, others
														Continued

Table 1 Patient characteristics in studies included in the meta-analysis. *Median (IQR); sp, standard deviation; PC, prospective cohort; RC, retrospective cohort; NA, not available; BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease

Obstructive sleep apnoea and postoperative outcome

Table 1 Continued

Study	Study design	Diagnosis of OSA	Groups	n	Age (yr) [mean (range)]	Male [n (%)]	BMI [mean (sd)]	HTN [n (%)]	DM [n (%)]	CAD [n (%)]	COPD [n (%)]	Asthma [n (%)]	Stroke [n (%)]	Surgery type
Kaw and colleagues ²¹	RC	PSG	OSA	37	62.9 (45.4–75.9)	29 (78.4)	31.7 (27.2 <i>–</i> 36.0)*	NA	8 (21.6)	6 (16.2)	6 (16.2)	NA	Cardiothoracic	
			Non-OSA	185	61.8 (35.5–90.0)	144 (77.8)	31.8 (26.9– 36.3)*	NA	37 (20.0)	22 (11.9)	20 (10.8)	NA		
Kaw and colleagues ²⁰	RC	PSG	OSA	262	56.1 (NA)	119 (44.4)	38.4	180 (66.7)	71 (263)	43 (16.0)	33 (12.2)	50 (18.5)	NA	Orthopaedic, thoracic, abdominal, gynaecologic, genitourinary,
			Non-OSA	209	46.7 (NA)	149 (55.6)	33.2	80 (39.6)	24 (11.9)	13 (16.4)	9 (4.5)	41 (20.3)	NA	Vascular, neurosurgical, Others
Luizaga and colleagues ³³	RC	PSG	OSA	69	42 (18.8–60.8)	15 (16.5)	50.6 (8.2)	NA	NA	NA	NA	NA	NA	Bariatric
			Non-OSA	22				NA	NA	NA	NA	NA	NA	
Sabers and colleagues ³¹	RC	PSG	OSA	234	57.0 (32.4–97.4)	171 (73.1)	35.5 (7.2)	102 (43.6)	28 (11.9)	26 (11.1)	9 (3.9)	16 (6.8)	NA	Orthopaedic, genitourinary, gynaecologic, abdominal, others
			Non-OSA	234	56.9 (20.5–91.0)	171 (73.1)	33.7 (7.2)	61 (26.1)	12 (5.1)	23 (9.8)	9 (3.9)	1 (0.4)	NA	
Vasu and colleagues ²⁹	RC	STOP-BANG questionnaire	OSA	56	64.7 (37.7-83.6)	22 (27.8)	NA	37 (66.1)	9 (16.1)	5 (8.9)	2 (3.6)	4 (7.1)	NA	Orthopaedic, gynaecologic, abdominal, genitourinary, vascular
			Non-OSA	79	53 (18.1-90.3)	38 (67.9)	NA	22 (27.8)	5 (6.3)	3 (3.8)	1 (1.3)	5 (6.3)	NA	ENT, cardiothoracic, others

BIA

Study	Study Design	Study population clearly identified?	Clear definition of outcome and outcome assessment?	Selective loss of patients during follow-up?	Important confounders and/prognostic factors identified?
Gupta and colleagues ¹⁹	RC	Yes	Yes	No	Adjusted for age, sex, operated side, type of operation, surgeon, mode of fixation of the components, year of operation, and type of anaesthesia
Sabers and colleagues ³¹	RC	Yes	Yes	No	Adjusted for type of anaesthesia, age, sex, BMI, surgical procedure, and surgical date
Kaw and colleagues ²¹	RC	Yes	Yes	No	Adjusted for BMI, weight, gender, race, smoking, emergency, diabetes, COPD/asthma, preoperative haematocrit, and CPB time
Gali and colleageus ³⁰	PC	Yes	Yes	Yes	No
Hallowell and colleagues ²⁸	RC	Yes	Yes	No	No
Ahmad and colleagues ¹⁸	PC	Yes	Yes	Yes	No
Chung and colleagues ³²	PC	Yes	Yes	No	No
Hwang and colleagues ¹⁷	RC	Yes	Yes	No	Adjusted for ODI4% group, sex and BMI group
Finkel and colleagues ²³	PC	Yes	Yes	Yes	No
Gali and colleagues ²⁷	PC	Yes	Yes	No	Adjusted for age, sex, BMI, and recurrent events
Kaw and colleagues ²⁰	RC	Yes	Yes	No	Adjusted for age, sex, race, BMI, type of anaesthesia, ASA class, and medical co-morbidities
Luizaga and colleagues ³³	RC	Yes	Yes	No	No
Vasu and colleagues ²⁹	RC	Yes	Yes	No	Adjusted for age, ASA class, risk of OSAS, and $\ensuremath{BMI^{25}}$

 Table 2
 Quality of the studies. RC, retrospective cohort; PC, prospective cohort; BMI, body mass index; ODI, oxygen desaturation index; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; OSAS, obstructive sleep apnoea syndrome

propensity for OSA.³⁵ The incidence of tachycardia as opposed to postoperative arrhythmias, and related use of i.v. metoprolol, ephedrine, and labetalol was significantly higher in the OSA group, despite the fact that a majority of these patients received regional anaesthesia. Surgical stress, including postoperative pain and endocrine changes, increases the sympathetic activation further. Episodic hypoxaemia during random eve movement sleep lead to brief arousals associated with profound sympathetic activation, which may cause haemodynamic instability and increased mean arterial pressure.^{39 40} Postoperative respiratory obstruction is associated with large fluctuations in systolic and diastolic arterial pressure measurement in patients with OSA, but this does not explain intraoperative changes. As a result of chronic adrenergic arousal, patients with sleep apnoea may have down-regulated α -receptors and β -receptors, and thus have an attenuated response to vasopressors.⁴¹

Transfer to ICU after surgery

Two studies had a major impact on our results.^{22 28} One reported the highest rate of ICU transfers (40% vs 28%;

P<0.01) and respiratory complications (33% vs 22%; P=0.01) in patients with OSA, although the majority of these transfers were planned.²² This study was however excluded from the analysis since the diagnosis of OSA was taken from the charts and the majority of the transfers to ICU were planned. In contrast, a higher rate of ICU transfer was reported for bariatric surgery patients without OSA (31% vs 69%).²⁸ However, when mandatory, PSG screening before surgery was used between 2004 and 2005 (phase 2); the overall rate of ICU transfer decreased (3.4% vs 5.6%). Phase 2 underestimates the effect of OSA on ICU transfer in postoperative patients, and other studies found higher rates of ICU transfer after surgery.¹⁹ ²¹ ²⁷ Most of these ICU transfers were unplanned.

There are several limitations to our analysis. Respiratory failure is the main postoperative complication in patients with OSA. However, no standard definition for ARF was used between the studies. Some studies were initiated as QI projects, while others reported prior CPAP use, both of which may have helped reduce postoperative ARF. Our subgroup analyses, however, show that associations between

BIA

		000		Non-O	190		Odde Patio	Odde Patio
Study	or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Ahmad	2008	0	31	0	9		Not estimable	
Chung	2008	10	147	2	64	12.9%	2.26 [0.48, 10.63]	
Gali 20	09	4	221	9	472	27.9%	0.95 [0.29, 3.11]	
Gupta 2	2001	16	101	9	101	37.5%	1.92 [0.81, 4.58]	+
Hwang	2008	3	98	1	74	5.5%	2.31 [0.23, 22.62]	
Kaw 20	06	0	37	2	185	4.1%	0.98 [0.05, 20.80]	
Kaw 20	09	9	270	0	202	2.7%	14.71 [0.85, 254.29]	
Sabers	2003	0	234	1	234	7.4%	0.33 [0.01, 8.19]	
Vasu 2	010	3	56	0	79	1.9%	10.40 [0.53, 205.48]	
Total (9	95% CI)		1195		1420	100.0%	2.07 [1.23, 3.50]	•
Total ev	vents	45		24				
Hetero	geneity: Chi ² = 6	5.14, df = 7	(P = 0.	52); l ² = 0)%			0.01 0.1 1 10 1
Test Ioi	overall effect.	2 = 2.72 (F	= 0.00					Favours OSA Favours Non-O
Posto	perative r	espirat	ory fa	ailure	SA		Odds Batio	Odds Batio
Study	or Subaroup	Events	Total	Events	Total	Weiaht	M-H. Fixed. 95% CI	M-H. Fixed, 95% Cl
Ahmad	2008	0	31	1	9	15.3%	0.09[0.00.2.41]	<
Finkel	2000	1	661	0	2117	1.6%	9 62 [0 39 236 37]	
Gali 20	09	'n	221	0	472		Not estimable	
Gunta	2001	a	101	2	101	12.8%	3.13 [0.62 15 87]	+
Kaw 20	06	5	37	16	185	31.5%	1.65 [0.56, 4.83]	- +
Kaw 20	09	16	270	4	202	29.4%	3.12 [1.03, 9.47]	⊢ _
Luizana	a 2010	0	69	0	22		Not estimable	
Sabers	2003	1	234	1	234	6.8%	1.00 [0.06. 16.08]	
Vasu 2	010	4	56	0	79	2.6%	13.63 [0.72, 258.43]	+
_								
Total (9	95% CI)	00	1680	<u>.</u>	3421	100.0%	2.43 [1.34, 4.39]	
I otal e	vents	33	(D)	24	E0/			
Hetero	geneity: $Chi^2 = i$	7.06, df = 6	(P = 0.3)	31); I ² = 1	5%			0.01 0.1 1 10 1
Test Io	overall effect: A	Z = 2.93 (P	= 0.00	5)				Favours OSA Favours Non-O
Reintu	ubation							
		OS/	۹ ۳۰۰۰	Non-0	DSA		Odds Ratio	Odds Ratio
Study	or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Finkel 2	2009	1	661	0	2117	3.0%	9.62 [0.39, 236.37]	
Gupta 2	2001	2	101	0	101	6.1%	5.10 [0.24, 107.58]	
Kaw 20	06	5	37	16	185	57.9%	1.65 [0.56, 4.83]	
Kaw 20	00	4	070					
	09	4	270		202	14.2%	3.02 [0.34, 27.25]	
Sabers	2003	4	270	1	202 234	14.2% 18.8%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19]	
Sabers	2003	4	270 234	1	202 234	14.2% 18.8%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19]	
Sabers Total (9	2003 95% CI)	40	270 234 1303	1	202 234 2839	14.2% 18.8% 100.0%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55]	•
Sabers Total (9 Total en	2003 2003 95% CI) vents	4 0 12 2 75 df = 4	270 234 1303	ו 1 18 60): וגי – נ	202 234 2839	14.2% 18.8% 100.0%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55]	•
Sabers Total (S Total ev Heterog Test for	2003 25% CI) vents geneity: Chi ² = 2 r overall effect: 2	4 0 12 2.75, df = 4 Z = 1.75 (P	270 234 1303 (P = 0.08)	1 18 60); I ² = 0	202 234 2839	14.2% 18.8% 100.0%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55]	0.01 0.1 10 1 Eavours OSA Eavours Non-C
Sabers Total (9 Total en Heterog Test for	2003 95% CI) vents geneity: Chi ² = 2 r overall effect: 2	4 0 12 2.75, df = 4 Z = 1.75 (P	270 234 1303 (P = 0.08)	1 18 60); l ² = 0	202 234 2839	14.2% 18.8% 100.0%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55]	0.01 0.1 1 10 1 Favours OSA Favours Non-C
Sabers Total (9 Total en Heterog Test for Posto	2003 2003 205% CI) vents geneity: Chi ² = 2 r overall effect: 2 perative d	12 2.75, df = 4 Z = 1.75 (P	270 234 1303 (P = 0.0 = 0.08) ation	18 60); l ² = 0	202 234 2839	14.2% 18.8% 100.0%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55]	0.01 0.1 1 10 1 Favours OSA Favours Non-C
Sabers Total (9 Total en Heterog Test for POSTO	2003 2003 95% CI) vents geneity: Chi ^p = 2 overall effect: 2 perative d	4 0 12 2.75, df = 4 Z = 1.75 (P desatur OSA Events	270 234 1303 (P = 0.0 = 0.08) ation	18 60); l ² = 0 Non-0 Events	202 234 2839)% SA Total	14.2% 18.8% 100.0% Weight	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] Odds Ratio M-H, Random, 95% (0.01 0.1 10 1 Favours OSA Favours Non-C Odds Ratio
Sabers Total (9 Total en Heterog Test for Posto <u>Study o</u> Ahmad	2003 2003 95% CI) vents pereity: Chi ² = 2 voverall effect: 2 perative d or Subgroup 2008	12 2.75, df = 4 Z = 1.75 (P desatur OSA <u>Events</u> 10	270 234 1303 (P = 0.08) ation <u>Total</u> 31	18 60); I ² = 0 Non-0 <u>Events</u> 4	202 234 2839)% SA Total 9	14.2% 18.8% 100.0% <u>Weight</u> 8.1%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] Odds Ratio M-H, Random, 95% (0.60 [0.13, 2.71	0.01 0.1 10 1 Favours OSA Favours Non-C Odds Ratio
Sabers Total (9 Total ev Heterog Test for Posto Study o Ahmad Chung	2003 25% CI) yents yents: voverall effect: : perative d prsubgroup 2008 2008	12 2.75, df = 4 Z = 1.75 (P desatur OSA <u>Events</u> 10 30	270 234 1303 (P = 0.08) ation <u>Total</u> 31 147	18 60); ² = 0 Non-O <u>Events</u> 4	202 234 2839)% SA <u>Total</u> 9 64	14.2% 18.8% 100.0% <u>Weight</u> 8.1% 11.5%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] Odds Ratio <u>M-H, Random, 95% (</u> 0.60 [0.13, 2.71 2.48 [0.98, 6.29	0.01 0.1 1 10 1 Favours OSA Favours Non-C Odds Ratio
Sabers Total (s Total ev Hetero Test for Posto Study a Chung Gali 20	009 2003 265% CI) yents geneity: Chi ^p = 2 geneity: Chi ^p = 2 r overall effect: : perative d prative d generative d pr Subgroup 2008 2008 07	4 0 12 2.75, df = 4 Z = 1.75 (P desatur 0 <u>SA</u> <u>Events</u> 10 30 47	270 234 1303 (P = 0.08) ation Total 31 147 115	18 60); ² = 0 Non-O <u>Events</u> 4 6 3	202 234 2839 % % SA Total 9 64 25	14.2% 18.8% 100.0% <u>Weight</u> 8.1% 11.5% 9.5%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.05 [0.92, 4.55] M-H, Random, 95% (0.60 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.9]	Odds Ratio
Sabers Total (S Total en Heterog Test for POStO Study of Ahmad Chung Gali 20 Gali 20	2003 2003 35% CI) vents geneity: Chi ² = 2 perative d pr Subgroup 2008 2008 2008 09	4 0 12 2.75, df = 4 2 = 1.75 (P lesatur 0SA <u>Events</u> 10 30 47 20	270 234 1303 (P = 0.0 = 0.08) ation <u>Total</u> 31 147 115 221	18 60); ² = 0 Events 4 6 3 54	202 234 2839 5% SA Total 9 64 25 472	14.2% 18.8% 100.0% <u>Weight</u> 8.1% 11.5% 9.5% 13.7%	3.02 [0.34, 27,25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.05 [0.92, 4.55] 0.60 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32	Odds Ratio
Sabers Total (Total er Heterog Test for Posto Study of Ahmad Chung Gali 20 Gali 20 Galy 20 Galy 20	009 2003 35% CI) yents peneity: Chi [≥] = 2 overall effect: : perative d or Subgroup 2008 2008 2008 07 09 2001	12 2.75, df = 4 Z = 1.75 (P Iesatur OSA Events 10 30 47 20 28	270 234 1303 (P = 0.08) ation Total 31 147 115 221 101	18 60); I ² = 0 Non-O <u>Events</u> 4 6 3 54 10	202 234 2839 0% SA Total 9 64 25 472 101	14.2% 18.8% 100.0% 8.1% 11.5% 9.5% 13.7% 12.4%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.60 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.9] 0.77 [0.45, 1.32 3.49 [1.59, 7.65	Odds Ratio
Sabers Total (Total en Heterog Test for Posto Study (Ahmad Chung Gali 20 Gali 20 Gupta 2 Hallowe	2003 2003 95% CI) vents geneity: Chi ² = 2 overall effect: 2 perative C br Subgroup 2008 2008 07 09 2001 ali 2007	12 2.75, df = 4 Z = 1.75 (P desatur 0SA <u>Events</u> 10 30 47 20 28 4	270 234 1303 (P = 0.08) ation Total 31 147 115 221 101 454	Non-O Events 4 60); ² = C 9 10 10 7	202 234 2839 0% SA Total 9 64 25 472 101 436	14.2% 18.8% 100.0% <u>Weight</u> 8.1% 11.5% 9.5% 13.7% 12.4% 9.6%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.60 [0.13, 271 2.48 [0.98, 6:29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.65 0.54 [0.16, 1.87	Odds Ratio
Sabers Total (Total en Heterog Test for Posto Study of Ahmad Chung Gali 20 Guita 2 Hallowe Hwang	2003 25% CI) yents geneity: Chi ² = 2 perative d or Subgroup 2008 2008 07 09 2001 301 2007 2008	4 0 12 2.75, df = 4 Z = 1.75 (P lesatur 0sA Events 10 30 47 20 28 4 4 6	270 234 1303 (P = 0.08) ation Total 31 147 115 221 101 454 98	18 60); l ² = 0 Non-O <u>Events</u> 4 6 3 54 10 7 1	202 234 2839 7% SA Total 9 64 25 472 25 472 101 436 74	14.2% 18.8% 100.0% 8.1% 11.5% 9.5% 13.7% 12.4% 9.6% 5.6%	3.02 [0.34, 27,25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.05 [0.92, 4.55] 0.060 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.66 0.54 [0.16, 1.87 4.76 [0.56, 40.43	Odds Ratio
Sabers Total (9 Total en Heterog Test for POSTO Ahmad Chung Gali 20 Gali 20 Ga	009 2003 35% CI) yents peneity: Chi ² = 2 overall effect: : perative d or subgroup 2008 2008 007 2008 007 2001 301 2007 2008 006	12 2.75, df = 4 Z = 1.75 (P desatur 0SA <u>Events</u> 100 30 47 20 28 4 6 5	270 234 1303 (P = 0.08) ation Total 31 147 115 221 101 454 98 37	18 60); I ² = 0 Non-O Events 4 6 3 54 10 7 1 16	202 234 2839 50% SA Total 9 64 25 472 101 436 74 185	14.2% 18.8% 100.0% 8.1% 11.5% 9.5% 13.7% 12.4% 9.6% 5.6% 10.6%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.60 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.66 0.54 [0.16, 1.87 4.76 [0.56, 40.43 1.65 [0.56, 4.83	Odds Ratio
Sabers Total (% Total ex Heteroo Test for Posto Ahmad Chung Gali 20 Gupta 2 Hallowe Hwang Kaw 20 Kaw 20	009 2003 95% CI) yents geneity: Chi ² = 2 overall effect: 2 perative d or Subgroup 2008 2008 2008 2008 2008 2001 3112007 2008 006 09	4 0 12 2.75, df = 4 Z = 1.75 (P desatur 0SA Events 10 300 47 20 288 4 6 5 27	270 234 1303 (P = 0.08) ation Total 31 147 115 221 101 454 98 37 270	18 600); ² = 0 Non-O Events 4 6 3 54 4 10 7 1 16 6 3	202 234 2839 7% SA Total 9 64 25 472 101 436 74 185 202	14.2% 18.8% 100.0% 8.1% 11.5% 9.5% 13.7% 12.4% 9.6% 5.6% 10.6% 9.8%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.05 [0.92, 4.55] 0.060 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.65 0.54 [0.16, 1.87 4.76 [0.56, 4.03 1.65 [0.56, 4.83 7.37 [2.20, 24.65	Odds Ratio
Sabers Total (f Total er Heterog Test for POSTO Study (Ahmad Chung Gali 20 Gupta 2 Hallow Hwang Kaw 20 Kaw 20 Sabers	2003 35% CI) vents peneity: Chi ² = 2 overall effect: : perative d or Subgroup 2008 2008 2008 2008 2008 2009 2000 109 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008	12 2.75, df = 4 Z = 1.75 (P desatur OsA <u>Events</u> 10 30 47 20 28 4 4 6 5 5 27 5	270 234 1303 (P = 0.08) ation Total 31 147 115 221 101 454 98 37 270 234	Non-O Events 60); ² = 0 <u>Events</u> 4 6 3 54 100 7 1 1 16 3 1	202 234 2839 7% SA Total 9 64 25 472 101 436 74 185 202 234	14.2% 18.8% 100.0% Weight 8.1% 11.5% 9.5% 13.7% 12.4% 9.6% 5.6% 10.6% 9.8% 5.5%	3.02 [0.34, 27,25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.05 [0.92, 4.55] 0.060 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.66 0.54 [0.16, 1.87 4.76 [0.56, 4.04 1.65 [0.56, 4.03 7.37 [2.20, 24.66 5.09 [0.59, 43.88	Odds Ratio
Sabers Total (Total ev Heteroy Test for Posto Study (Ahmad Chung Gali 20 Gupta 2 Hallowe Hwang Kaw 20 Sabers Vasu 2	009 2003 35% CI) yents peneity: Chi ² = 2 overall effect: 2 perative d or subgroup 2008 2008 2008 2008 2007 2008 2007 2008 00 2008 00 2003 00 00 2003 00 00 2003 00 00 00 00 00 00 00 00 00	12 2.75, df = 4 Z = 1.75 (P desatur OSA Events 10 30 47 20 28 4 6 5 5 7 7	270 234 1303 (P = 0.08) ation 31 147 115 221 101 454 98 37 270 234 56	Non-O Events 4 60); I ² = 0 54 10 7 1 16 3 1 0	202 234 2839 % % SA Total 9 64 25 472 101 436 74 472 101 436 74 202 234 79	14.2% 18.8% 100.0% Weight 8.1% 11.5% 9.5% 13.7% 5.6% 10.6% 9.8% 5.5% 3.7%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.60 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.65 0.54 [0.16, 1.87 4.76 [0.56, 4.043 1.65 [0.56, 4.83 7.37 [2.20, 24.65 5.09 [0.59, 43.88 24.09 [1.35, 43.115	Odds Ratio
Sabers Total (% Total ev Heterog Test for POSTO Study (Ahmad Chung Gali 20 Gupta 2 Hallowe Hwang Kaw 20 Sabers Vasu 2 Total (%	009 2003 35% CI) yents yents: perative d or Subgroup 2008 07 2008 07 2008 07 2008 07 2008 00 2003 00 2003 00 2003 00 2003 00 2003 00 2003 00 2003 00 2003 00 2003 00 2003 00 2005 2005 00 00 00 00 00 00 00 00 00	4 0 12 2.75, df = 4 Z = 1.75 (P desatur 0SA Events 10 30 47 20 28 4 6 5 27 5 7	270 234 1303 (P = 0.08) ation Total 31 147 115 221 101 454 98 37 270 270 274 56	Non-O Events 4 60); I ² = 0 5 4 6 3 5 4 10 7 1 16 3 1 0 0	202 234 2839 30% SA Total 9 64 25 472 185 74 72 185 74 72 234 79 1881	14.2% 18.8% 100.0% Weight 8.1% 11.5% 9.5% 13.7% 12.4% 9.6% 5.6% 10.6% 9.8% 5.5% 3.7% 100.0%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.060 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.65 0.54 [0.16, 1.87 4.76 [0.56, 4.83 7.37 [2.20, 24.65 5.09 [0.59] 4.33.8 24.09 [1.35, 431.15 2.27 [1.20, 4.26	Odds Ratio
Sabers Total (Total en Heteroy Test for POSTO Study of Ahmad Chung Gali 20 Gali 20 Gali 20 Gali 20 Gali 20 Gabra 2 Hallow Hwang Kaw 20 Sabers Vasu 21 Total (009 2003 2003 2003 2004 2005 2007 2008 2008 2008 2008 2008 2008 2009 2001 2001 2001 2001 2007 2008 009 2003 001 009 2003 001 009 2003 001 009 2003 001 009 2003 001 009 2003 001 009 2003 001 009 2003 001 009 2003 001 009 2003 009 2003 009 2003 009 2003 009 2003 009 2003 009 2003 009 2003 009 2003 009 2003 009 2003 009 2003 2005	12 2.75, df = 4 2 = 1.75 (P desatur desatur 10 30 47 20 28 4 6 5 27 5 7 189	270 234 1303 (P = 0 = 0.08) ation Total 31 147 115 221 101 454 98 37 270 234 66 1764	18 18 60); ² = 0 Non-O Events 4 6 3 54 10 7 1 16 3 1 0 105	202 234 2839 30% SA Total 9 9 64 25 472 101 436 74 185 202 234 436 74 185 202 234 436 74 185	14.2% 18.8% 100.0% Weight 8.1% 11.5% 9.5% 13.7% 12.4% 9.6% 5.6% 10.6% 9.8% 5.5% 3.7% 100.0%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.05 [0.92, 4.55] 0.060 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.65 0.54 [0.16, 1.87 4.76 [0.56, 40.43 1.65 [0.56, 4.83 7.37 [2.20, 24.65 5.09 [0.59, 4.388 24.09 [1.35, 431.15 2.27 [1.20, 4.26]	Odds Ratio
Sabers Total (Total en Heteroo Test for POSTO Study (Ahmad Chung Gali 20 Gupta 2 Hallowe Hwang Kaw 20 Sabers Vasu 2: Total en Hotal en Sabers Vasu 2: Total en Hotal en Hotal en Hotal en Hotal en Sabers Vasu 2: Total en Hotal en Hota	009 2003 35% CI) vents peneity: Chi ² = 2 r overall effect: : perative d or subgroup 2008 2008 2008 2008 2008 2009 2008 2009 2003 2010 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2003 2007 2	- 4 0 12 2.75, df = 4 Z = 1.75 (P lesatur 0SA Events 10 30 30 208 4 6 5 5 7 7 1889 9.068 : Chi ²	270 234 1303 (P = 0.08) ation Total 31 147 115 221 201 224 37 270 234 56 1764 = 31.53.	18 18 60); ² = 0 Non-O Events 4 6 3 54 10 7 1 16 3 1 0 105 df = 10 (202 234 2839 7% SA Total 9 64 255 202 234 79 1851 202 234 79 1881 202	14.2% 18.8% 100.0% 8.1% 11.5% 13.7% 12.4% 9.6% 5.6% 9.8% 5.6% 3.7% 10.6% 9.8% 5.5% 3.7%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.60 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.22 3.49 [1.59, 7.65 0.54 [0.16, 1.37 4.76 [0.56, 40.43 1.65 [0.56, 4.43 7.37 [2.20, 24.65 5.09 [0.59, 43.88 24.09 [1.35, 431.15 2.27 [1.20, 4.26]	Odds Ratio
Sabers Total (Total en Heteroo Test for POSTO Ahmad Chung Gali 20 Gupta 2 Hallowe Hwang Kaw 20 Sabers Vasu 2! Total en Heteroo Test for	009 2003 35% CI) vents peneity: Chi ² = 2 overall effect: : perative d or subgroup 2008 2008 2008 2008 2008 2008 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2008 2009 2008 2009 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2009 2008 2003 2008 2003 2008 2003 2008 2003 2008 2008 2008 2003 2008 208		270 234 1303 (P = 0. = 0.08) ation Total 147 115 221 147 115 221 147 145 224 56 234 56 1764 = 31.53, = 0.01)	1 18 60); I ² = C Events 4 6 6 54 10 7 1 16 3 3 54 10 0 7 1 105 6 df = 10 (202 234 2839 7% SA Total 9 9 4 25 472 10 436 74 185 202 234 79 1881 P = 0.0	14.2% 18.8% 100.0% 8.1% 11.5% 13.7% 12.4% 9.6% 5.6% 9.8% 5.6% 3.7% 10.6% 9.8% 5.5% 3.7%	3.02 [0.34, 27,25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.60 [0.13, 2,71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.65 0.54 [0.16, 1.37 4.76 [0.56, 40.43 1.65 [0.56, 4.43 7.37 [2.20, 24.65 5.09 [0.59, 43.88 24.09 [1.35, 431.15 2.27 [1.20, 4.26]	Odds Ratio Odds Ratio M-H, Random, 95% Cl
Sabers Total et Heterog Test for POSTO Study of Ahmad Chung Gali 20 Gupta 2 Hallow Hwang Kaw 20 Sabers Vasu 2 Total et Heterog Test for	2003 2003 2003 2003 2004 2005 2005 2004 2008 2008 2008 2008 2008 2008 2007 2008 2003 2003 2003 2003 010 2003 2003 010 2005 2003 2004 2005	4 0 12 2.75, df = 4 2 = 1.75 (P 4 2 = 1.75 (P 0 SA Events 10 30 47 7 20 28 4 6 5 7 189 0.68; Chi ² - 5 7 189 0.68; Chi ² - 2 = 2.54 (P	270 234 1303 (P = 0.1 = 0.08) ation Total 31 147 115 221 101 454 8 37 270 234 56 1764 = 31.53, = 0.01)	Non-O Events 4 6 3 54 10 7 1 16 3 1 0 0 105 6 df = 10 (202 234 2839 % % SA Total 9 64 255 472 101 436 472 101 436 74 79 1881 P = 0.00	14.2% 18.8% 100.0% Weight 8.1% 11.5% 9.5% 13.7% 12.4% 9.6% 5.6% 10.6% 9.8% 5.5% 3.7% 100.0%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.05 [0.92, 4.55] 0.060 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.65 0.54 [0.16, 1.87 4.76 [0.56, 4.83 7.37 [2.20, 24.65 5.09 [0.59, 4.388 24.09 [1.35, 431.15 2.27 [1.20, 4.26] 38%	Odds Ratio Odds Ratio M-H, Random, 95% Cl 0.01 0.1 10 1 Favours OSA Favours Non-C
Sabers Total (Total en Heterog Test for POSTO Study (Ahmad Chung Gali 20 Gali 20 Gal	2003 2003 35% CI) yents peneity: Chi ² = 2 overall effect: : perative d or Subgroup 2008 2008 2008 2008 2008 2001 311 2007 2008 2003 2003 2003 2003 2003 2003 2003 2003 2003 2003 2003 2003 2003 2003 2003 2003 2004 2005 200	12 2.75, df = 4 2 = 1.75 (P desatur 0SA Events 10 30 47 20 28 4 6 5 7 7 189 0.68; Chi ² Z = 2.54 (P CU trar	270 234 1303 (P = 0.08) ation Total 31 147 1147 101 454 98 37 270 234 56 1764 = 31.53, = 0.01) msfer	Non-O Events 4 6 3 5 4 6 3 3 1 1 0 7 1 1 6 3 3 1 0 0 0 0 5 4 6 3 3 5 4 4 6 3 3 5 4 4 6 3 3 5 4 4 10 10 10 10 10 10 10 10 10 10 10 10 10	202 234 2839 3% SA Total 9 64 25 202 202 9 64 472 101 436 472 101 436 274 185 202 234 79 1861 P = 0.00	14.2% 18.8% 100.0% Weight 8.1% 11.5% 13.7% 12.4% 9.6% 5.6% 9.8% 5.5% 10.6% 9.8% 5.5% 100.0% 100.0%	3.02 [0.34, 27,25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 2.05 [0.92, 4.55] 0.60 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.99, 7.65 0.54 [0.16, 1.87 4.76 [0.56, 4.83 7.37 [2.20, 24.65 5.09 [0.59, 43.88 24.09 [1.35, 431.15 2.27 [1.20, 4.26]	Odds Ratio M-H, Random, 95% Cl M-H, Random, 95% Cl 0.01 0.1 10 1 Favours OSA Favours Non-Cl 0.01 0.1 10 1 Favours OSA Favours Non-Cl
Sabers Total (Total en Heteroo Test for POSTO Study of Ahmad Chung Gali 20 Gupta 2 Hallowe Hwang Kaw 20 Sabers Vasu 2 Total en Heteroo Total en Heteroo Total en Heteroo Sabers	009 2003 35% CI) yents peneity: Chi ² = 2 overall effect: 2 perative d or Subgroup 2008 2008 2008 2008 2008 2007 2008 2007 2008 2003 2004 2005 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2008 2007 2008 2008 2007 2008 2008 2007 2008 2008 2007 2008 2008 2007 2008 2008 2008 2008 2008 2007 2008 208	12 2.75, df = 4 2 = 1.75 (P estatur 0SA Events 10 30 0 4 6 5 27 5 7 189 0.68; Chi ² - Z = 2.54 (P CU trar 0SA Events 0SA	270 234 1303 (P = 0.08) ation Total 31 15 221 101 454 98 37 270 234 56 1764 = 31.53, 56	18 18 18 18 19 19 10 10 10 10 10 10 10 10 10 10	202 234 2839 % 50 50 50 50 50 50 50 50 50 50 50 50 50	14.2% 18.8% 100.0% Weight 8.1% 9.5% 13.7% 12.4% 9.6% 5.6% 9.8% 5.5% 10.6% 9.8% 5.5% 100.0% Weight 100.0%	3.02 [0.34, 27,25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 2.05 [0.92, 4.55] 0.60 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.98, 6.29 5.07 [1.43, 17.91 0.77 [0.56, 4.04 3.165 [0.56, 4.04 7.37 [2.20, 24.65 5.09 [0.59, 43.88 24.09 [1.35, 431.15 2.27 [1.20, 4.26] 38%	Odds Ratio
Sabers Total et Heterog Test for Posto Study of Ahmad Chung Gali 20 Gupta 2 Hallow Hwang Kaw 20 Sabers Vasu 2: Total et Heterog Test for Posto Sabers Vasu 2: Total et Heterog Test for Posto	2003 2003 2003 2003 2003 2004 2005 2004 2007 2008 2008 07 2008 07 2008 07 2008 07 2008 07 2008 07 2008 07 2008 06 09 2003 010 2003 010 2003 010 2003 010 2004 2005 2	12 2.75, df = 4 2 = 1.75 (P 2 2.75, df = 4 2 = 1.75 (P 2 2 2 2 2 3 3 0 4 7 2 0 2 8 4 6 5 7 7 1 89 0.68; Chi ² 2 5 7 7 0.68; Chi ² 2 2 = 2.54 (P CU trar 2 2 2 2 5 7 7 1 2 9 0.68; Chi ² 4 2 2 5 7 7 1 2 9 0.68; Chi ² 4 2 2 2 5 7 7 1 2 9 0.68; Chi ² 4 2 2 2 5 7 7 1 2 2 2 5 5 7 7 1 2 2 2 5 5 7 7 1 2 2 2 5 5 7 7 1 2 2 2 5 5 7 7 1 2 2 5 7 7 1 2 2 2 5 5 7 7 1 2 5 7 7 7 1 2 9 1 2 9 1 2 9 1 2 7 1 2 9 1 2 1 2	270 234 1303 (P = 0.08) ation <u>Total</u> 31 147 7 270 234 454 98 37 270 234 454 98 37 270 234 454 98 37 270 234 454 98 37 270 234 115 56	Non-OC Events 105 105 105 105 105 105 105 105 105 105	202 234 2839 7% SA Total 9 64 472 101 436 74 1436 74 436 74 234 74 1881 P = 0.00 88 1881 64 64	14.2% 18.8% 100.0% Weight 8.1% 11.5% 9.5% 13.7% 12.4% 9.6% 5.6% 10.6% 9.8% 5.5% 10.0% 005); l ² = 6 Weight 7.1%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 2.05 [0.92, 4.55] 0.60 [0.13, 2.7] 2.48 [0.98, 6.29 5.07 [1.43, 17.9] 0.77 [0.45, 132 3.49 [1.59, 7.65 0.54 [0.16, 1.87 4.76 [0.56, 4.83 7.37 [2.20, 24.65 5.09 [0.59, 43.88 24.09 [1.35, 431.15 2.27 [1.20, 4.26] 38% Odds Ratio <u>M-H, Random, 95% C</u>	Odds Ratio M-H, Random, 95% Cl Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-C
Sabers Total (Total er Heterog Test for Posto Study (Ahmad Chung Gali 20 Gupta 2 Hallowe Hwang Kaw 20 Sabers Vasu 2! Total er Heterog Test for Posto Study of Chung 2 Sabers Vasu 2! Total er Heterog Test for Posto	2003 35% CI) vents peneity: Chi ² = 2 r overall effect: : perative C or Subgroup 2008 2008 2008 2008 2008 2009 2008 2007 2008 2007 2008 2	+ 4 0 12 2.75, df = 4 Z = 1.75 (P desatur OSA Events 10 30 28 4 6 5 27 5 7 189 0.68; Chi [∞] : Z = 2.54 (P CU trar CU trar CU trar 12 12	2740 1303 (P = 0.0 = 0.08) ation Total 31 147 115 221 1147 1221 101 454 98 837 270 234 56 1764 = 31.53, = 0.01) msfer Total 147 147 156 661	1 18 18 60); I² = C Events 4 6 3 54 10 7 11 16 3 54 4 6 3 54 100 7 11 16 3 105 df = 10 (Non-OC Events 1 0	202 234 2839 58 <u>Total</u> 9 4 4 25 4 72 101 4 36 79 1881 P = 0.00 8 8 Total P = 0.00 5 8 79 1881 P = 0.00 5 5 79 5 79 5 79 5 79 79 79 79 79 79 79 79 79 79 79 79 79	14.2% 18.8% 100.0% Weight 8.1% 11.5% 9.5% 13.7% 12.4% 9.6% 5.6% 3.7% 100.0% 005); l ² = 6 Weight 7.1% 3.6%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.060 [0.13, 2,71 2.46 [0.98, 6.29 5.07 [1.43, 17.9] 0.77 [0.45, 1.32 3.49 [1.59, 7.65 0.54 [0.16, 1.37 4.76 [0.56, 40.43 1.65 [0.56, 40.43 1.65 [0.56, 43.33 7.37 [2.20, 24.65 5.09 [0.59, 43.38 24.09 [1.35, 431.15 2.27 [1.20, 4.26] 38% Odds Ratio M-H, Random, 95% C 5.60 [0.71, 44.02] 9.62 [0.39, 236, 37]	Odds Ratio
Sabers Total (Total en Heteroo Test for POSTO Study (Ahmad Chung Gali 20 Gupta 2 Hallows Hwang Kaw 20 Sabers Vasu 2 Total en Heteroo Total en Heteroo Test for POSTO	009 2003 22003 35% CI) yents geneity: Chi ² = 2 perative d 2008 pr Subgroup 2008 2003 2008 2003 2008 2003 2001 all 2007 2008 2003 001 95% CI) yents geneity: Tau ² = : overall effect: 1 perative If If yents 1 perative If 1 perative If 1	12 2.75, df = 4 2 = 1.75 (P desatur 0SA Events 10 30 0 4 4 6 5 27 7 189 0.68; Chi ² + Z = 2.54 (P CU trar 0SA Events 12 12 12 12 12 12 12 12 12 12	274 1303 (P = 0 = 0.08) ation Total 31 15 221 101 454 98 37 270 0234 56 1764 = 31.53, 56 1764 = 0.01) msfer 147 661 147	1 18 18 60); I² = C Events 4 6 3 54 10 7 11 16 3 10 7 11 16 3 10 0 105 0 0	202 234 2839 2839 7% 5A Total 9 64 25 472 10 436 74 72 185 202 234 472 185 202 234 472 185 1881 P = 0.0 5 6 4 72 164 213 79 5 6 7 79 6 70 70 70 70 70 70 70 70 70 70 70 70 70	14.2% 18.8% 100.0% Weight 8.1% 9.5% 13.7% 12.4% 9.6% 5.6% 3.7% 10.6% 9.8% 5.5% 3.7% 100.0% 005); l ² = 6 Weight 7.1% 3.6% 4.2%	3.02 [0.34, 27,25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 2.05 [0.92, 4.55] 0.60 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.93, 7.66 0.54 [0.16, 1.87 4.76 [0.56, 4.04 7.37 [2.20, 24.65 5.09 [0.59, 43.88 24.09 [1.35, 431.15 2.27 [1.20, 4.26] 38% Odds Ratio MH, Random, 95% C 5.60 [0.71, 44.02] 9.62 [0.39, 236.37] 2.54 [0.14, 47.39]	Odds Ratio M-H, Random, 95% Cl Odds Ratio M-H, Random, 95% Cl
Sabers Total et Heterog Test for Posto Study of Ahmad Chung Gali 20 Gupta 2 Hallowe Hwang Kaw 20 Sabers Vasu 21 Total et Heterog Test for Posto Study of Chung 2 Study of Chung 2 Finkel 2 Gali 200 Gupta 2 Study of Chung 2 Sing 20 Chung 20 Sing 20 Chung	2003 2003 2003 2003 2003 2008 2008 2008 2008 2008 2008 2007 2008 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2008 2007 2008 2007 2008 2008 2009 2008 2008 2008 2009 2008 2009 2008 2008 2009 2008 2008 2009 2008 2008 2009 2008 2008 2009 2008 2008 2009 2008	12 2.75, df = 4 2 = 1.75 (P lesatur OSA Events 10 30 47 20 28 4 6 5 27 7 0.68; Chi ² : Z = 2.54 (P CU trar OSA Events 12 1 5 16 5 16 12 12 1 5 16 16 12 12 12 12 16 16 16 16 16 16 16 16 16 16	2740 1303 (P = 0 = 0.08) ation Total 31 147 145 221 147 56 1764 = 31.53, = 0.01) nsfer Total 147 661 115 221	1 18 18 60); I² = C Events 4 6 3 10 7 16 3 10 0 105 2 105 0 105 0 0 0 0 0	202 234 2839 9% SA Total 9 64 425 472 101 436 74 436 74 436 74 436 74 102 234 9 64 436 74 103 888 109 64 212 234 9 9 64 436 74 202 234 9 9 64 436 74 203 9 9 64 74 203 9 9 64 74 203 9 9 64 74 203 9 74 203 9 9 64 74 203 9 74 203 9 74 203 9 74 203 9 74 203 9 74 203 9 74 203 9 74 203 74 203 74 74 203 74 74 203 74 74 74 74 74 74 74 74 74 74 74 74 74	14.2% 18.8% 100.0% Weight 8.1% 11.5% 9.5% 13.7% 12.4% 5.6% 10.6% 5.5% 3.7% 100.0% 005); l ² = 6 Weight 7.1% 3.6% 4.2%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 2.05 [0.92, 4.55] 0.60 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.65 0.54 [0.16, 1.87 4.76 [0.56, 4.83 7.37 [2.20, 24.65 5.09 [0.59, 43.88 24.09 [1.35, 431.15 2.27 [1.20, 4.26] 38% 0dds Ratio M-H, Random, 95% C 5.60 [0.71, 44.02] 9.62 [0.39, 236.37] 2.54 [0.14, 47.39]	Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-C Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-C Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-C Odds Ratio
Sabers Total (Total er Heterog Test for POSTO Study (Ahmad Chung Gali 20 Gupta 2 Hallowe Hwang Kaw 20 Sabers Vasu 2! Total er Heterog Test for POSTO Study of Sudy 2 Sabers Vasu 2! Total er Heterog Test for Study of Chung 2 Finkel 2! Gali 20 Gali 20 Gupta 2 Total (Sabers) Sudy 2 Total er Heterog Test for Study of Chung 2 Finkel 2! Gali 20 Gali 20 Gali 20 Chung 2 Study 0 Chung 2 Study 0 Study 0 Chung 2 Study 0 Study 0 Stud	2003 2003 35% CI) vents peneity: Chi ² = 2 or overall effect: : perative d or Subgroup 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 06 09 2003 010 05% CI) vents peneity: Tau ² = 1 overall effect: : perative l r Subgroup 2008 2003 010 05% CI) vents peneity: Tau ² = 1 r overall effect: : perative l r Subgroup 2008 2003 010 05% CI) vents r overall effect: : perative l r Subgroup 2008 2009 7 99 001	12 2.75, df = 4 2 = 1.75 (P lesatur 0SA Events 10 30 28 4 6 5 7 189 0.68; Chi ² ; 2 = 2.54 (P CU trar 0SA Events 12 12 1 5 16 22 12 16 22 12 16 12 16 22 12 16 12 16 12 16 12 16 16 16 16 16 16 16 16 16 16	2730 1303 (P = 0.0 = 0.08) ation Total 31 147 137 145 221 101 454 98 98 97 270 0 1764 = 31.53, = 0.01) mSfer Total 147 157 101 101 105 105 105 105 105 105	Non-O 100 100 100 100 100 100 100 100 100 100 100 100 100 105 105 105 105 105 105 105 105 100 </td <td>202 234 2839 7% SA Total 9 64 25 472 25 472 202 472 101 64 64 203 279 1881 P = 0.00 64 2117 25 472 217 25 472 21 64 21 64 21 64 21 64 21 64 21 25 9 64 21 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 20 9 9 64 25 20 9 9 64 25 20 9 9 64 20 10 10 10 10 10 10 10 10 10 10 10 10 10</td> <td>14.2% 18.8% 100.0% Weight 8.1% 9.5% 13.7% 9.5% 13.7% 9.6% 5.6% 5.6% 3.7% 10.6% 9.8% 5.5% 3.7% 100.0% 005); I² = € Weight 7.1% 3.6% 17.3%</td> <td>3.02 [0.34, 27,25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.60 [0.13, 2,71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.65 0.54 [0.16, 1.87 4.76 [0.56, 4.04 7.37 [2.20, 24.65 5.09 [0.59, 4.33 7.37 [2.20, 24.65 5.09 [0.71, 44.73] 9.62 [0.39, 236.37] 2.54 [0.14, 47.39] 4.02 [1.75, 9.24] 4.02 [1.75, 9.24]</td> <td>Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-O 0.01 0.1 10 1 G1 M-H, Random, 95% CI 0.01 0.1 10 1 Favours OSA Favours Non-O 0.01 0.1 10 1 Favours OSA Favours Non-O</td>	202 234 2839 7% SA Total 9 64 25 472 25 472 202 472 101 64 64 203 279 1881 P = 0.00 64 2117 25 472 217 25 472 21 64 21 64 21 64 21 64 21 64 21 25 9 64 21 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 9 9 64 25 20 9 9 64 25 20 9 9 64 25 20 9 9 64 20 10 10 10 10 10 10 10 10 10 10 10 10 10	14.2% 18.8% 100.0% Weight 8.1% 9.5% 13.7% 9.5% 13.7% 9.6% 5.6% 5.6% 3.7% 10.6% 9.8% 5.5% 3.7% 100.0% 005); I² = € Weight 7.1% 3.6% 17.3%	3.02 [0.34, 27,25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.60 [0.13, 2,71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.65 0.54 [0.16, 1.87 4.76 [0.56, 4.04 7.37 [2.20, 24.65 5.09 [0.59, 4.33 7.37 [2.20, 24.65 5.09 [0.71, 44.73] 9.62 [0.39, 236.37] 2.54 [0.14, 47.39] 4.02 [1.75, 9.24] 4.02 [1.75, 9.24]	Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-O 0.01 0.1 10 1 G1 M-H, Random, 95% CI 0.01 0.1 10 1 Favours OSA Favours Non-O 0.01 0.1 10 1 Favours OSA Favours Non-O
Sabers Total (% Total en Heterog Test for Posto Study of Ahmad Chung Gali 200 Gupta 2 Hallowe Hwang Kaw 200 Sabers Vasu 20 Sabers Vasu 20 Sabers Cotal e e Heteroq Test for Study of Guing 2 Situdy of Guing 2 Sinkel 20 Gali 200 Gupta 2 Hallow	009 2003 25% CI) vents geneity: Chi² = 2 overall effect: 3 perative d overall effect: 3 postative d overall effect: 3 perative l overall effect: 3	4 0 12 2.75, df = 4 Z = 1.75 (P desatur 0SA Events 10 30 047 20 28 4 6 5 27 5 7 7 189 0.68; Chi ² ; Z = 2.54 (P CU trar CU trar 12 1 5 5 2 2 2 2 2 2 2 5 4 4 6 5 7 7 7 7 7 8 7 7 7 8 7 8 8 8 8 8 8 8 8	274 1303 (P = 0.08) ation Total 31 147 270 234 454 98 37 270 234 454 147 165 147 161 115 221 147 161 155 221 107 147 165 167 167 167 167 167 167 167 176 167 176 176	Non-OC Events 105 105 105 105 105 105 105 105 105 105	2022 234 2839 9 64 225 472 234 472 1435 202 234 472 1435 202 234 79 1881 P = 0.00 8 8 79 1881 P = 0.00 8 79 1881 202 234 9 6 4 21 203 9 6 4 21 203 9 6 4 203 9 6 4 205 9 6 4 205 9 6 4 205 9 6 4 205 9 6 4 205 9 6 4 205 9 6 4 205 9 6 4 205 9 6 4 205 9 6 4 205 9 6 4 205 9 6 4 205 9 6 4 205 205 205 205 205 205 205 205 205 205	14.2% 18.8% 100.0% Weight 8.1% 11.5% 9.5% 13.7% 12.4% 9.6% 5.6% 10.6% 9.8% 5.5% 100.0%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 2.05 [0.92, 4.55] 0.60 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.65 0.54 [0.16, 1.87 4.76 [0.56, 4.83 7.37 [2.20, 24.65 5.09 [0.59, 43.83 2.4.09 [1.35, 431.15 2.27 [1.20, 4.26] 3.8% Odds Ratio M-H, Random, 95% C 5.60 [0.71, 44.02] 9.62 [0.39, 236.37] 2.54 [0.14, 47.39] 4.02 [1.75, 9.24] 3.24 [1.37, 7.67] 0.83 [0.44, 1.53]	Odds Ratio M-H, Random, 95% Cl M-H, Random, 95% Cl M-H, Random, 95% Cl M-H, Random, 95% Cl M-H, Random, 95% Cl
Sabers Total (Total ex- Heterog Test for Posto Study of Ahmad Chung Gali 200 Gupta 2 Hallowe Hwang Kaw 202 Sabers Vasu 2! Total (Total ex- Heterog Gali 200 Gupta 2 Hallowe Kaw 202 Sabers Vasu 2! Total ex- Heterog Test for Posto Study of Chung 2 Finkel 2! Gali 200 Gupta 2 Heterog Test for Posto	009 2003 2003 2003 2003 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2007 2008 2008 2008 2007 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2001 2007 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2	$^{+}$ $^{+}$	2740 1303 (P = 0 = 0.08) ation <u>Total</u> 147 115 221 101 454 98 837 270 224 56 1764 = 31.53, = 0.01) nsfer <u>Total</u> 147 147 147 101 454 221 101 454 37	1 18 18 60); I² = C Events 4 6 3 54 10 7 11 16 3 10 105 df = 10 (0 9 8 233 14	2022 234 2839 % SA Total 9 44 255 472 101 4366 74 79 1881 P = 0.00 SA Total P = 0.00 SA Total 2032 9 472 2039 9 64 2039 7 7 9 64 2039 7 7 9 64 2039 7 7 9 64 2039 7 7 9 64 2039 7 7 9 64 2039 7 7 9 64 2039 7 7 9 64 2039 7 7 9 64 2039 7 7 9 64 2039 7 7 9 64 2039 7 7 9 64 2039 7 7 9 64 2039 7 7 9 7 7 9 7 8 7 7 9 7 7 9 7 9 7 9 7	14.2% 18.8% 100.0% Weight 8.1% 11.5% 9.5% 13.7% 12.4% 9.6% 5.5% 3.7% 100.0% 005); l ² = 6 Weight 7.1% 3.6% 4.2% 17.0% 19.9% 13.6%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 0.60 [0.13, 2.71 2.46 [0.98, 6.29 5.07 [1.43, 17.9] 0.77 [0.45, 1.32 3.49 [1.59, 7.65 0.54 [0.16, 1.37 4.76 [0.56, 40.43 1.65 [0.56, 40.43 1.65 [0.56, 41.33 7.37 [2.20, 24.65 5.09 [0.75, 43.88 24.09 [1.35, 431.15 2.27 [1.20, 4.26] 38% Odds Ratio M-H, Random, 95% C 5.60 [0.71, 44.02] 9.62 [0.39, 2263.37] 2.54 [0.14, 47.39] 4.02 [1.75, 9.24] 3.24 [1.37, 767] 0.83 [0.45, 1.53] 1.48 [0.46, 4.78]	Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-C Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-C Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-C Odds Ratio
Sabers Total (% Total en Heteroo Test for POSTO Study (Ahmad Chung (Gali 200 Gali 200 Gali 200 Sabers Vasu 21 Total en Heteroo Test for POSTO Sudy 20 Sabers Vasu 21 Total en Heteroo Test for POSTO Study 0 Chung 2 Finkel 21 Gali 200 Gali 200 Gali 200 Chung 2 Finkel 21 Gali 200 Gali 200 Gali 200 Chung 2 Finkel 21 Gali 200 Gali 200 Chung 2 Finkel 21 Gali 200 Gali 200 Gali 200 Chung 2 Finkel 21 Gali 200 Gali 200 Chung 2 Finkel 21 Gali 200 Gali 200 Chung 2 Finkel 21 Gali 200 Gali 200 Chung 2 Finkel 21 Gali 200 Chung 2 Finkel 20 Gali 200 Chung 2 Finkel 21 Gali 200 Chung 2 Finkel 21 Chung 2 Finkel 21 Finkel 21 Ch	009 2003 35% CI) vents peneity: Chi ² = 2 overall effect: : perative d or Subgroup 2008 2008 2008 2008 2008 2007 2008 2008 2007 2008 2008 2003 2007 2008 2007 2008 2003 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2007 2008 2008 2007 2008 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2009 2008 2008 2009 2008 2008 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2008 2009 2008 2008 2008 2008 2009 2008 2008 2007 2008 2007 2008		2740 234 1303 (P = 0.08) ation Total 31 131 131 131 101 454 98 37 270 0 56 1764 147 661 147 661 147 661 101 454 37 2270	1 18 18 60); I² = C Events 4 6 3 54 4 6 3 54 10 7 11 16 3 54 100 7 11 16 20 df = 10 (Non-OS 10 0 9 8 23 14 3	202 234 2839 7% SA Total 9 9 4 25 472 234 472 185 202 234 79 1881 P = 0.0 SA Total P = 0.0 SA Total 436 64 2117 25 472 101 64 2117 25 202 234 9 9 6 6 7 7 8 105 7 7 9 9 6 6 7 7 7 8 105 7 7 9 7 8 7 7 7 7 8 7 7 7 7 7 7 7 7 7 7	14.2% 18.8% 100.0% Weight 8.1% 9.5% 13.7% 12.4% 9.6% 5.6% 9.8% 5.5% 10.6% 9.8% 5.5% 10.6% 9.8% 5.5% 10.0% 005); l ² = 6 Weight 7.1% 3.6% 4.2% 17.0% 19.9% 13.6% 13.1%	3.02 [0.34, 27, 25] 0.33 [0.01, 8, 19] 2.05 [0.92, 4, 55] 2.05 [0.92, 4, 55] M-H, Random, 95% C 0.60 [0.13, 2, 71 2.48 [0.98, 6, 29 5.07 [1.43, 17, 91 0.77 [0.45, 1, 32 3.49 [1.59, 7, 66 0.54 [0.16, 187 4.76 [0.56, 40.43 7.37 [2.20, 24, 65 5.09 [0.59, 43, 88 24.09 [1.35, 431.15 2.27 [1.20, 4, 26] 38% Odds Ratio M-H, Random, 95% C 5.60 [0.71, 44, 02] 9.62 [0.39, 236, 37] 2.54 [0.14, 47, 39] 4.02 [1.75, 9, 24] 3.24 [1.37, 7, 67] 0.83 [0.45, 1.53] 1.48 [0.46, 4.73] 1.48 [0.46, 4.73]	Odds Ratio M-H, Random, 95% Cl Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-Cl Odds Ratio M-H, Random, 95% Cl Odds Ratio
Sabers Total (% Total er Heterog Test for Posto Study of Ahmad Chung Gali 200 Gupta 2 Hallowe Heterog Total er Heterog Total er Heterog Total (% Posto Sabers Vasu 20 Sabers Vasu 20 Sabers Vasu 20 Chung 2 Finkel 20 Gali 200 Gupta 2 Heterog Total er Heterog Total er Heterog Test for Study on Chung 2 Finkel 20 Gali 200 Gupta 2 Hallowe Kaw 200 Xaw 20	009 2003 25% CI) yents yents yents yenerstive C yenerstive C yenerative C yenerative C yenerative	4 0 12 2.75, df = 4 Z = 1.75 (P desatur 0SA Events 10 30 047 20 28 4 6 5 27 5 7 7 189 0.68; Chi ² : Z = 2.54 (P CU trar CU trar 12 1 5 6 6 8 CH ² = 2.54 (P CU trar 12 1 5 16 22 20 04 21 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	270 234 1303 (P = 0.08) ation Total 31 147 7270 234 56 1764 = 31.53, 56 1764 = 31.53, 56 1147 661 115 221 101 147 661 56 56	Non-OC Events 4 6 3 3 54 4 10 7 1 16 3 3 4 4 6 3 3 5 4 4 0 0 7 7 1 16 6 3 3 5 4 4 0 0 7 7 1 1 6 6 8 8 8 5 4 8 10 9 8 8 8 10 10 10 10 10 10 10 10 10 10 10 10 10	202 234 2839 9 64 25 472 102 234 472 11 436 79 1881 P = 0.0 8 8 7 9 6 4 72 234 79 1881 P = 0.0 9 6 4 72 234 79 9 6 4 72 17 25 202 234 9 6 4 72 17 25 9 6 4 72 17 25 9 6 4 72 17 25 9 6 4 72 17 25 9 6 4 72 17 25 9 6 4 72 17 25 9 6 4 72 17 25 79 6 4 72 17 25 79 6 4 72 79 6 4 72 79 6 4 72 79 6 4 72 79 79 6 4 72 79 79 6 4 72 79 79 6 4 72 79 79 6 4 72 79 79 6 4 72 79 79 79 6 4 72 79 79 79 79 79 70 70 79 79 70 70 70 70 70 70 70 70 70 70 70 70 70	14.2% 18.8% 100.0% Weight 8.1% 11.5% 9.5% 13.7% 12.4% 5.6% 10.6% 9.8% 5.5% 100.0% 005); l ² = 6 Weight 7.1% 3.6% 4.2% 17.3% 19.9% 13.6% 13.1% 4.1%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 2.05 [0.92, 4.55] 0.60 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.65 0.54 [0.16, 1.87 4.76 [0.56, 4.83 7.37 [2.20, 24.65 5.09 [0.59, 43.83 2.4.09 [1.35, 431.15 2.27 [1.20, 4.26] 5.88% Odds Ratio M-H, Random, 95% C 5.60 [0.71, 44.02] 9.62 [0.39, 238.37] 2.54 [0.14, 47.39] 4.02 [1.75, 9.24] 3.24 [1.37, 767] 0.83 [0.45, 1.53] 1.48 [0.46, 4.78] 5.59 [1.65, 19.22] 3.63 [0.72, 285.43]	Odds Ratio M-H, Random, 95% Cl Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-C Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-C M-H, Random, 95% Cl
Sabers Total (% Total ex- Heterog Test for POSTO Study of Ahmad Chung Gali 200 Gupta 2 Hallowe Hwang Kaw 202 Sabers Vasu 21 Total ex- Heterog Sabers Vasu 22 Sabers Vasu 22 Total ex- Heterog Test for Study of Chung 2 Finkel 2 Gali 200 Gupta 2 Heterog Test for POSTO	009 2003 25% CI) vents yensity: Chi ² = 2 overall effect: 3 perative d overall effect: 3 post and the second	$^{+}$ 0 12 2.75, df = 4 Z = 1.75 (P desatur OSA Events 10 30 47 28 4 6 5 27 7 189 0.68; Chi ² - Z = 2.54 (P CU trar 0SA Events 12 15 16 20 4 21 4 21 4 21 22 24 24 24 24 25 25 27 25 25 27 25 25 27 25 25 27 25 25 25 27 25 25 25 25 25 25 25 25 25 25	2740 1303 (P = 0.0 = 0.08) ation Total 31 147 145 221 101 454 98 837 270 234 56 1764 = 31.53, = 0.01) nsfer Total 147 147 270 56	1 18 18 60); I² = C Events 4 6 3 54 10 7 11 16 3 54 4 6 3 54 6 3 105 0 105 0 9 8 23 14 3 0	202 234 2839 % SA Total 9 44 25 472 101 436 74 202 234 79 1881 P = 0.0 SA Total P = 0.0 SA Total 101 436 202 79	14.2% 18.8% 100.0% Weight 8.1% 11.5% 9.5% 13.7% 12.4% 9.6% 5.6% 3.7% 100.0% 005); l ² = 6 Weight 7.1% 3.6% 4.2% 17.0% 17.0% 17.0% 13.7% 13.1% 4.1%	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 2.05 [0.92, 4.55] 0.60 [0.13, 2, 71 2.46 [0.98, 6.29 5.07 [1.43, 179] 0.77 [0.45, 1.32 3.49 [1.59, 7.65 0.54 [0.16, 1.37 4.76 [0.56, 40.43 1.65 [0.56, 40.43 1.65 [0.56, 40.43 1.65 [0.56, 43.38 7.37 [2.20, 24.65 5.09 [0.75, 43.88 24.09 [1.35, 431.15 2.27 [1.20, 4.26] 38% Odds Ratio M-H, Random, 95% C 5.60 [0.71, 44.02] 9.62 [0.39, 2263.37] 2.54 [0.14, 47.39] 4.02 [1.75, 9.24] 3.24 [1.37, 767] 0.83 [0.45, 1.59] 1.463 [0.46, 4.78] 5.59 [1.65, 19.02] 13.63 [0.72, 258.43]	Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-C Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-C Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-C
Sabers Total (% Total ex- Heterog Test for POSTO Study (Ahmad Chung Gali 200 Gupta 2 Hallowe Hwang Kaw 202 Sabers Vasu 2! Total (% Total ex- Heterog Test for POSTO Study of Chung 2 Finkel 2! Gali 200 Gali 200 Chung 2 Finkel 2! Gali 200 Gali 200 Chung 2 Finkel 2! Gali 200 Gali 200 Chung 2 Finkel 2! Gali 200 Chung 2 Finkel 2! Chung 2 Finkel 2! Finkel 2! Chung 2	009 2003 35% CI) vents peneity: Chi ² = 2 overall effect: : perative d or subgroup 2008 2001 2007 2008 2008 2007 2008	12 2.75, df = 4 Z = 1.75 (P lesatur OSA Events 10 30 0 28 4 6 5 7 7 189 0.68; Chi ² 2 = 2.54 (P CU trar 0SA Events 12 1 5 16 22 20 4 4 1 1 5 5 7	2740 234 1303 (P = 0.08) ation Total 31 131 131 131 101 454 98 8 37 270 234 56 1764 = 31.53, 234 56 1764 = 31.53, 56 115 221 147 661 147 661 115 2270 56 2062	Non-OC Events 4 4 6 3 3 54 4 10 7 1 16 3 3 54 4 10 7 1 16 3 3 54 4 10 7 1 16 6 3 54 4 10 0 7 8 54 4 10 0 7 8 11 10 10 10 10 10 10 10 10 10 10 10 10	202 234 2839 3% 5A Total 9 9 4 25 472 202 234 79 1881 P = 0.0 5A Total 185 202 234 234 79 1881 P = 0.0 54 64 2117 25 24 472 101 64 2117 25 202 234 9 9 4 235 9 9 4 25 202 234 9 9 4 25 202 234 9 9 4 25 202 234 9 9 4 25 202 234 9 9 4 25 202 203 9 9 4 25 203 9 9 4 25 202 203 9 9 4 25 203 203 9 9 4 25 203 203 203 203 203 203 203 203 203 203	14.2% 18.8% 100.0% Weight 8.1% 11.5% 13.7% 12.4% 9.6% 5.6% 9.8% 5.5% 3.7% 10.6% 9.8% 5.5% 3.7% 10.0% 005); l ² = 6 Weight 7.1% 3.6% 17.0% 3.6% 13.1% 14.2% 14.2% 15.5% 16.6% 10.6% 10	3.02 [0.34, 27.25] 0.33 [0.01, 8.19] 2.05 [0.92, 4.55] 2.05 [0.92, 4.55] 0.60 [0.13, 2.71 2.48 [0.98, 6.29 5.07 [1.43, 17.91 0.77 [0.45, 1.32 3.49 [1.59, 7.66 0.54 [0.16, 1.87 4.76 [0.56, 4.03 7.37 [2.20, 24.65 5.09 [0.59, 43.88 24.09 [1.35, 43.115 2.27 [1.20, 4.26] 38% Odds Ratio M-H, Random, 95% C 5.60 [0.71, 44.02] 9.62 [0.39, 236.37] 4.02 [1.75, 9.24] 3.24 [1.37, 7.67] 0.83 [0.45, 1.53] 1.48 [0.46, 4.73] 1.55 [1.65, 10.02] 13.63 [0.72, 258.43] 2.81 [1.46, 5.43]	Odds Ratio M-H, Random, 95% Cl Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-Cl Odds Ratio M-H, Random, 95% Cl Odds Ratio
Sabers Total (% Total en Heterog Test for Posto Study of Ahmad Chung Gali 20 Gupta 2 Hallow Hwang Kaw 20 Sabers Vasu 20 Total en Heterog Test for Posto Study of Chung 2 Finkel 20 Gali 200 Gupta 2 Heterog Test for Study of Chung 2 Finkel 20 Gali 200 Gupta 2 Heterog Test for Total en Kaw 200 Chung 2 Finkel 20 Gali 200 Gupta 2 Hallow Kaw 200 Chung 2 Finkel 20 Gali 200 Gupta 2 Finkel 20 Gali 200 Chung 2 Finkel 20 Gali 200 Gupta 2 Finkel 20 Gali 200 Chung 2 Finkel 20 Gali 200 Gupta 2 Finkel 20 Chung 2 Finkel 20 Gali 200 Gupta 2 Finkel 20 Gali 200 Gupta 2 Finkel 20 Gali 200 Gupta 2 Finkel 20 Finkel 20 Fin	009 2003 35% CI) yents pensity: Chi ² = 2 overall effect: : perative C or Subgroup 2008 2008 007 2003 007 2008 007 2008 007 2008 007 2008 007 2003 007 2003 007 2003 007 2003 007 2003 007 2008 009 007 2008 009 007 11 2007 2008 009 11 2007 2008 009 11 2007 2008 009 11 2007 2008 009 11 2007 2008 009 11 2007 2008 009 11 2007 2008 009 11 2007 2008 009 11 2007 2008 009 11 2007 2008 009 11 2007 2008 009 11 2007 2008 009 10 10 2007 2008 009 10 10 2007 206 009 10 10 205% CI) ents	12 2.75, df = 4 Z = 1.75 (P desatur OSA Events 10 30 47 20 28 4 6 5 5 7 7 8 8 8 4 4 6 5 5 7 7 8 7 8 9 0.68; Chi ² - 2.254 (P CU trar 0SA Events 12 2.254 (P 2.25, df = 4 2.27 5 7 5 7 189 9 0.68; Chi ² - 2.254 (P 2.25, df = 4 2.25 2.25 2.25 2.25 2.25 2.25 2.25 2.2	270 234 1303 (P = 0.08) ation Total 31 147 5221 115 5221 114 454 98 37 270 234 56 1764 = 31.53, 37 270 147 661 115 221 117 115 56 221 107 56 2062	Non-OC Events 4 6 3 3 54 4 10 0 7 1 16 3 3 10 5 0 (df = 10 0 0 0 9 8 8 23 14 3 0 0 58	202 234 2839 9 64 25 472 102 234 472 11 436 79 1881 P = 0.0 8 8 79 1881 P = 0.0 8 79 1881 1881 202 234 472 117 25 202 234 472 10 14 185 202 234 9 64 214 214 214 214 214 214 214 214 214 21	14.2% 18.8% 100.0% Weight 8.1% 11.5% 9.5% 13.7% 12.4% 5.6% 10.6% 9.8% 5.5% 100.0% 100.0% 100.0% Weight 7.1% 3.6% 4.2% 17.3% 17.4% 17.3% 17.3% 17.3% 17.3% 17.3% 17.3% 17.3% 17.3% 17.3% 17.4% 17.6% 17.3% 17.3% 17.3% 17.3% 17.3% 17.4% 17.3% 17.3% 17.4% 17.3% 17.4% 17.3% 17.4% 17.3% 17.4% 17.3% 17.4% 17.3% 17.4% 17.4% 17.3% 17.4% 17.3% 17.4	3.02 [0.34, 27,25] 0.33 [0.01, 8,19] 2.05 [0.92, 4,55] 2.05 [0.92, 4,55] 0.60 [0.13, 2,71 2.48 [0.98, 6,29 5.07 [1.43, 17,91 0.77 [0.45, 1,32 3.49 [1.59, 7,65 0.54 [0.16, 1,87 4.76 [0.56, 4,83 7.37 [2.20, 24,65 5.09 [0.59, 43,84 2.4,09 [1.35, 43,15 2.27 [1.20, 4,26] 5.60 [0.71, 44,02] 9.62 [0.39, 238,37] 2.54 [0.14, 47,39] 4.02 [1.75, 9,24] 3.24 [1.37, 767] 0.83 [0.45, 1,53] 1.48 [0.46, 4,78] 5.59 [1.65, 19.02] 13.63 [0.72, 258,43] 2.81 [1.46, 5.43]	Odds Ratio M-H, Random, 95% Cl Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-C Odds Ratio 0.01 0.1 10 1 Favours OSA Favours Non-C Odds Ratio

Fig 2 Forest plots of postoperative outcomes.

OSA and ARF remained unchanged, except among studies initiated as QI. Although we reached statistical significance with postoperative cardiac events in patients with OSA, inconsistent reporting between studies and wide range of cardiac and haemodynamic variables reported make the interpretation of this analysis difficult. Two recent studies, one of which had a large sample size, had to be excluded from the analysis for reasons discussed above. And lastly, meta-analysis by design is a univariate analysis and not adjusted for other variables.

In conclusion, patients with OSA undergoing non-cardiac surgery have a higher incidence of postoperative respiratory desaturation, respiratory failure, cardiac events, and ICU transfers than those without OSA.

Authors' contributions

Study concept and design: R.K., F.C., and A.V.H. Acquisition of data: V.P., J.M., R.K., A.V.H., and F.C. Analysis and interpretation of data: A.V.H., R.K., F.C., and P.C.G. Drafting of the manuscript: R.K., A.V.H., V.P., and J.M. Critical revision of the manuscript for intellectual content: A.V.H., R.K., F.C., and P.C.G. Statistical analysis: A.V.H. and R.K. Study supervision: R.K., A.V.H., F.C., and P.C.G.

Supplementary material

Supplementary material is available at *British Journal of Anaesthesia* online.

Declaration of interest

None declared.

Funding

No funding or financial support was received from any organization.

References

- 1 Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; **328**: 1230–5
- Bixler EO, Vgontzas AN, Ten HT. Effects of age on sleep apnea in men: 1. Prevalence and severity. Am J Respir Crit Care Med 1998; 157: 144-8
- 3 Bixler EO, Vgontzas AN, Lin HM. Prevalence of sleep-disordered breathing in women: effect on gender. *Am J Respir Crit Care Med* 2001; **163**: 608-13
- 4 Peker Y, Kraiczi H, Hedner J. An independent association between obstructive sleep apnoea and coronary artery disease. *Eur Respir J* 1999; 14: 179–84
- 5 Mehra R, Benjamin EJ, Shahar E. Association of nocturnal arrhythmias with sleep-disordered breathing: the Sleep Heart Health Study. *Am J Respir Crit Care Med* 2006; **173**: 910–6
- 6 Arzt M, Young T, Finn L. Association of sleep-disordered breathing and the occurrence of stroke. Am J Respir Crit Care Med 2005; 172: 1447-51

- 7 Coughlin SR, Mawdsley L, Mugarza JA. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. *Eur Heart J* 2004; **25**: 735–41
- 8 Chung F, Ward B, Ho J, Yuan H, Kayumov L, Shapiro C. Preoperative identification of sleep apnea risk in elective surgical patients using the Berlin questionnaire. J Clin Anesth 2007; 19: 130-4
- 9 O'Keeffe T, Patterson EJ. Evidence supporting routine polysomnography before bariatric surgery. *Obes Surg* 2004; **14**: 23–6
- 10 Malow BA, Levy K, Maturen K, Bowes R. Obstructive sleep apnea is common in medically refractory epilepsy patients. *Neurology* 2000; **55**: 1002–7
- 11 Pollak L, Shpirer I, Rabey JM, Klein C, Schiffer J. Polysomnography in patients with intracranial tumors before and after operation. *Acta Neurol Scand* 2004; **109**: 56–60
- 12 Hallowell PT, Stellato TA, Schuster M, *et al.* Potentially life threatening sleep apnea is unrecognized without aggressive evaluation. *Am J Surg* 2007; **193**: 364–7
- 13 Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology 2008; **108**: 812–21
- 14 Kaw R, Michota F, Jaffer A, Ghamande , Auckley D, Golish J. Unrecognized sleep apnea in the surgical patient: implications for the perioperative setting. *Chest* 2006; **129**: 198–205
- 15 Isono S. Obstructive sleep apnea of obese adults: pathophysiology and perioperative airway management. *Anesthesiology* 2009; **110**: 908–21
- 16 Saigusa H, Suzuki M, Higurashi N, Kodera K. Three-dimensional morphological analyses of positional dependence in patients with obstructive sleep apnea syndrome. *Anesthesiology* 2009; **110**: 885–90
- 17 Hwang D, Shakir N, Limann B, et al. Association of sleepdisordered breathing with postoperative complications. Chest 2008; 133: 1128–34
- 18 Ahmad S, Nagle A, McCarthy RJ, Fitzgerald PC, Sullivan JT, Prystowsky J. Postoperative hypoxemia in morbidly obese patients with and without obstructive sleep apnea undergoing laparoscopic bariatric surgery. *Anesth Analg* 2008; **107**: 138–43
- 19 Gupta R, Parvizi J, Hanssen AD, Gay PC. Postoperative complications in patients with obstructive sleep apnea syndrome undergoing hip or knee replacement: a case-control study. *Mayo Clin Proc* 2001; **76**: 897–905
- 20 Kaw R, Pasupuleti V, Walker E, Ramaswamy A, Foldvary-Schafer N. Postoperative complications in patients with obstructive sleep apnea. *Chest* 2012; **141**: 436–41
- 21 Kaw R, Golish J, Ghamande S, Burgess R, Foldvary N, Walker E. Incremental risk of obstructive sleep apnea in cardiac surgical outcomes. J Cardiovasc Surg (Torino) 2006; **47**: 683–9
- 22 Liao P, Yegneswaran B, Vairavanathan S, Zilberman P, Chung F. Postoperative complications in patients with obstructive sleep apnea: a retrospective cohort matched study. *Can J Anaesth* 2009; **56**: 819–28
- 23 Finkel KJ, Searleman AC, Tymkew H. Prevalence of undiagnosed obstructive sleep apnea among adult surgical patients in an academic medical center. *Sleep Med* 2009; **10**: 753–8
- 24 Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-Analysis of Observational Studies in Epidemiology (MOOSE) group. J Am Med Assoc 2000; **283**: 2008–12
- 25 Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; **6**: e1000097

- 26 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–58
- 27 Gali B, Whalen FX, Schroeder DR, Gay PC, Plevak DJ. Identification of patients at risk for postoperative respiratory complications using a preoperative obstructive sleep apnea screening tool and post-obstructive anesthesia care assessment. Anesthesiology 2009; 110: 869–77
- 28 Hallowell PT, Stellato TA, Petrozzi MC, et al. Eliminating respiratory intensive care until stay after gastric bypass surgery. Surgery 2007; 142: 608–12
- 29 Vasu TS, Doghramji K, Cavallazi R, *et al.* Obstructive sleep apnea syndrome and postoperative complications. *Arch Otolaryngol Head Neck Surg* 2010; **136**: 1020-4
- 30 Gali B, Whalen FX, Gay PC, *et al.* Management plan to reduce risks in perioperative care of patients with presumed obstructive sleep apnea syndrome. *J Clin Sleep Med* 2007; **3**: 582–8
- 31 Sabers C, Plevak DJ, Schroeder DR, Warner DO. The diagnosis of obstructive sleep apnea as a risk factor for unanticipated admissions in outpatient surgery. *Anesth Analg* 2003; **96**: 1328–35
- 32 Chung F, Yegneswaran B, Liao P, *et al.* Validation of the Berlin questionnaire and American Society of Anesthesiologists checklist as screening tools for obstructive sleep apnea in surgical patients. *Anesthesiology* 2008; **108**: 822–30
- 33 Luizaga E, Shah NA, Shah PA, et al. Prevalence of postoperative pulmonary complications in patients with obstructive sleep apnea undergoing bariatric surgery. Am J Respir Crit Care Med 2010; **181**: A3665
- 34 Memtsoudis S, Liu SS, Ma Y, et al. Perioperative pulmonary outcomes in patients with sleep apnea after non-cardiac surgery. *Anesth Analg* 2011; **112**: 113–21
- 35 Stierer TL, Wright C, George A, Thompson RE, Wu CL, Collop N. Risk assessment of obstructive sleep apnea in a population of patients undergoing ambulatory surgery. J Clin Sleep Med 2010; 6: 467–72
- 36 Yumino D, Tsurumi Y, Takagi A, *et al.* Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. *Am J Cardiol* 2007; **99**: 26–30

- 37 Lee CH, Khoo SM, Tai BC. Obstructive sleep apnea in patients admitted for acute myocardial infarction. Prevalence, predictors and effect on microvascular perfusion. Chest 2009; 135: 1488–95
- 38 Shah NA, Yaggi HK, Concato J, Mohsenin V. Obstructive sleep apnea as a risk factor for coronary events or cardiovascular death. Sleep Breath 2010; 14: 131-6
- 39 Knill RL, Skinner MI, Novick T, *et al.* The night of intense REM sleep after anesthesia and surgery increases urinary catecholamines (abstract). *Can J Anaesth* 1990; **37**: S12
- 40 Mancia G. Autonomic modulations of the cardiovascular system during sleep. *N Engl J Med* 1993; **328**: 347–9
- 41 Grote L, Kraizci H, Hedner J. Reduced alpha and beta-2 vascular adrenergic response in patients with obstructive sleep apnea. Am J Resp Crit Care Med 2000; 162: 1480-7

Appendix

PubMed search strategy

('Obstructive sleep apnoea' (All Fields) or 'sleep apnea, obstructive' (MeSH Terms) or ['sleep' (All Fields) and 'apnea' (All Fields) and 'obstructive' (All Fields)] or 'obstructive sleep apnea' (All Fields) or ['obstructive' (All Fields) and 'sleep' (All Fields) and 'apnea' (All Fields)]} or {'sleep apnoea' (All Fields) or 'sleep apnea syndromes' (MeSH Terms) or ['sleep' (All Fields) and 'apnea' (All Fields) and 'syndromes' (All Fields)] or 'sleep apnea syndromes' (All Fields) or ['sleep' (All Fields) and 'apnea' (All Fields)] or 'sleep apnea' (All Fields)} or {'obstructive sleep apnoea syndrome' (All Fields) or 'sleep apnea, obstructive' (MeSH Terms) or ['sleep' (All Fields) and 'apnea' (All Fields) and 'obstructive' (All Fields)] or 'obstructive sleep apnea' (All Fields) or ['obstructive' (All Fields) and 'sleep' (All Fields) and 'apnea' (All Fields) and 'syndrome' (All Fields)] or 'obstructive sleep apnea syndrome' (All Fields)} and ['anaesthesia' (All Fields) or 'anesthesia' (MeSH Terms) or 'anesthesia' (All Fields)] or perioperative (All Fields), and ['complications' (Subheading) or 'complications' (All Fields)].